Indication: Autoimmune disease

This week in therapeutics
Autoimmune disease
Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An in vitro screen identified B7-H2 as a ligand of CD28. In stimulated T cells, a B7-H2-blocking antibody lowered T cell proliferation compared with a control antibody. Next steps include studying the role of B7-H2 in inflammatory tissue. SciBX 4(21); doi:10.1038/scibx.2011.591 Published online May 26, 2011 Patent application filed; Amplimmune Inc. has an option to license the invention Yao, S. et al. Immunity; published online April 27, 2011; doi:10.1016/j.immuni.2011.03.014 Contact: Lieping Chen, Yale School of Medicine, New Haven, Conn. e-mail: lieping.chen@yale.edu
Cancer
Breast cancer CUE domain containing 2 (CUEDC2) In vitro studies suggest lowering CUEDC2 levels could help increase breast cancer response to hormonal therapy. In human breast cancer cell lines, CUEDC2 overexpression decreased sensitivity to the generic estrogen receptor antagonist tamoxifen compared with that seen using a control plasmid. In human breast tumor samples, CUEDC2 expression was higher than that in adjacent normal tissues and correlated with tamoxifen resistance and poor clinical outcomes. Next steps include validating CUEDC2 as a new biomarker for endocrine therapy and developing a small molecule inhibitor of CUEDC2 to overcome tamoxifen resistance. SciBX 4(21); doi:10.1038/scibx.2011.592 Published online May 26, 2011 Patent applications filed for diagnostic and therapeutic applications; available for licensing Pan, X. et al. Nat.

Read the full 2499 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE